猪鼻支原体减毒活疫苗候选株的研制与效力试验
本研究通过NTG诱变获得温度敏感型猪鼻支原体减毒株,与佐剂联合免疫3周龄仔猪,6周龄时静脉攻毒两天。免疫组临床评分(p=0.03)、大体病理(p=0.01)和组织病理(p=0.005)均显著低于阳性对照组,攻毒后特异性IgG抗体升高更早更高,但未减轻感染对增重的影响。
要点
- 减毒活疫苗候选株联合佐剂可显著减轻猪鼻支原体感染所致临床与病理损伤。
- 免疫组攻毒后特异性IgG抗体应答较阳性对照组更早且更强。
- 疫苗未能改善感染导致的增重下降。
核心结论
- 温度敏感型猪鼻支原体减毒株联合佐剂对猪鼻支原体感染提供保护,可作为新型疫苗候选株开发基础。
研究设计与样本
- 采用NTG诱变获得温度敏感型猪鼻支原体减毒株,与佐剂联合免疫3周龄仔猪,6周龄时连续两天静脉攻毒,设阳性对照和阴性对照。
主要发现
- 免疫组临床评分显著低于阳性对照组(p=0.03)。
- 免疫组大体病理病变显著低于阳性对照组(p=0.01)。
- 免疫组组织病理病变显著低于阳性对照组(p=0.005)。
- 攻毒后免疫组猪鼻支原体特异性IgG抗体水平较阳性对照组升高更早且更高。
- 攻毒后第21-42天,免疫组(p=0.001)和阳性对照组(p=0.003)增重均低于阴性对照组。
关键数值与推荐
- 免疫组临床评分较阳性对照组显著降低(p=0.03)。
- 免疫组大体病理评分较阳性对照组显著降低(p=0.01)。
- 免疫组组织病理评分较阳性对照组显著降低(p=0.005)。
- 攻毒后第21-42天免疫组增重低于阴性对照组(p=0.001)。
- 攻毒后第21-42天阳性对照组增重低于阴性对照组(p=0.003)。
临床怎么用
- 该候选疫苗可减轻猪鼻支原体感染的临床与病理损伤,但需关注其对增重无改善作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycoplasma (M.) hyorhinis causes substantial economic losses in swine. Currently, prevention and treatment rely on minimizing risk factors and administering antibiotics, as no vaccines are commercially available in Europe. However, antibiotics often cannot fully eliminate the bacteria. The development of an effective vaccine could lead to a potentially long-term control method. MATERIALS AND METHODS: A temperature-sensitive M. hyorhinis strain was developed using 1-methyl-3-nitro-1-nitrosoguanidine (NTG) mutagenesis. The immunogenicity and efficacy of this vaccine candidate clone were evaluated in combination with an adjuvant. Three-week-old piglets were immunized with the candidate vaccine strain, and the vaccination site was monitored daily. At six weeks of age, the pigs were challenged intravenously on two subsequent days. Daily clinical examinations were conducted, with blood and nasal swabs collected weekly throughout the study for M. hyorhinis enzyme-linked immunosorbent assay (ELISA), real-time PCR analysis, and isolation. Three weeks post-challenge, the animals were euthanized for gross and histopathological examinations. Body temperature was recorded daily, and body weight was measured upon arrival, and then at six and nine weeks of age. RESULTS: Vaccination significantly reduced clinical signs (p = 0.03), as well as gross pathological (p = 0.01) and histopathological (p = 0.005) lesions compared with the positive control group. The vaccinated group exhibited an earlier and higher increase in M. hyorhinis-specific IgG antibody levels post-challenge than the positive control group. However, the vaccine candidate did not mitigate the impact of M. hyorhinis infection on the weight gain. After the challenge (days 21-42), both the vaccinated (p = 0.001) and the positive control (p = 0.003) groups exhibited reduced weight gain compared with the negative control group. DISCUSSION: Overall, the attenuated M. hyorhinis strain, combined with the adjuvant, provided protection against M. hyorhinis infection. These results form a basis for the development of a novel vaccine candidate that offers effective prevention.
引用
- Nagy EZ, Szeredi L, Földi D, et al. Development and efficacy test of a live, attenuated Mycoplasma hyorhinis vaccine candidate strain. Vaccine. 2026. PMID: 41610462. doi:10.1016/j.vaccine.2026.128278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。